STOCK TITAN
  1. Home
  2. Sec-filings
  3. SHPH
  4. [8-K/A] Shuttle Pharmaceuticals Holdings, Inc. Amends Material Event Report

Shuttle Pharmaceuticals corrects warrant count to 9.74M

The corrected count distinguishes warrants issued as of September 9 from the maximum issuable after all conditions are satisfied.

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
8-K/A

Rhea-AI Filing Summary

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) amended its Item 3.02 disclosure to state that 9,741,751 pre-funded warrants had been issued as of September 9, 2026. The earlier approximately 16,932,508 figure represented the maximum number of Pre-Funded Warrants that could be issued upon satisfaction of all issuance conditions, not the number issued as of September 9. The amendment made no other changes to the disclosed information.

Positive

  • None.

Negative

  • None.
Item 3.02 Unregistered Sales of Equity Securities Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Pre-Funded Warrants issued 9,741,751 pre-funded warrants Issued as of September 9, 2026
Maximum Pre-Funded Warrants Approximately 16,932,508 Pre-Funded Warrants Maximum number that may be issued upon satisfaction of all issuance conditions
Pre-Funded Warrants financial
"issued pre-funded warrants"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many SHPH pre-funded warrants were issued as of September 9, 2026?
Shuttle Pharmaceuticals Holdings, Inc. stated that 9,741,751 pre-funded warrants had been issued as of September 9, 2026. The approximately 16,932,508 figure was the maximum number that could be issued upon satisfaction of all conditions, not the number issued as of September 9.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
true 0001757499 0001757499 2026-09-09 2026-09-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K/A

(Amendment No. 1)

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of report (date of earliest event reported): September 9, 2026

 

SHUTTLE PHARMACEUTICALS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41488   82-5089826

(State or other jurisdiction

of incorporation)

  

Commission

File Number

  

(IRS Employer

Identification No.)

 

401 Professional Drive, Suite 260

Gaithersburg, MD 20879

(Address of principal executive offices) (Zip Code)

 

(240) 430-4212

(Registrant’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock $0.00001 per share   SHPH   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

EXPLANATORY NOTE

 

On September 15, 2026, Shuttle Pharmaceuticals Holdings, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Form 8-K”) under Item 3.02 disclosing, among other things, that the Company issued pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of approximately 16,932,508 shares of Common Stock, which number actually represents the maximum number of Pre-Funded Warrants that may be issued upon the satisfaction of all conditions to issuance, and not the number of Pre-Funded Warrants that were issued as of September 9, 2026. The Company hereby amends the Form 8-K to reflect that, as of September 9, 2026, the actual number of Pre-Funded Warrants that have been issued is 9,741,751.

 

This Current Report on Form 8-K/A amends the Form 8-K solely to amend Item 3.02 as described above. There are no other modifications or updates to any of the information made in the Form 8-K.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
     
104   Cover Page Interactive Data File (embedded within the inline XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: September 24, 2026  
   
  SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
     
  By: /s/ Christopher Cooper
  Name: Christopher Cooper
  Title: Co-Chief Executive Officer

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents

Keep reading

More on SHPH

Trending in the feed

Open the live feed